What did analysts do for CMPX on March 05, 2026?

On March 05, 2026 both William Blair and Raymond James maintained an Outperform rating on CMPX. Raymond James tied its reiteration to Q4 results. Neither firm issued a new CMPX price target in the published summaries

Does the March 05, 2026 coverage include a CMPX price target?

No. The two StreetInsider summaries for March 05, 2026 reiterated Outperform but did not publish a new CMPX price target. Investors should consult full analyst reports or filings for any detailed valuation changes

What does a maintained Outperform mean for CMPX investors?

A maintained Outperform means analysts still expect CMPX to outperform peers. It does not guarantee immediate upside. Investors should weigh the rating alongside clinical catalysts, cash runway, and broader biotech sector trends

How should I use the Meyka AI grade for CMPX?

Meyka AI rates CMPX with a grade of B, combining benchmark, sector, growth, metrics, and analyst consensus. Use the grade as a starting point, not as advice, and combine it with primary research and analyst reports

Analyst Ratings

CMPX: William Blair and Raymond James Maintain Outperform March 2026

ByHuzaifa Zahoor March 6, 2026

On March 05, 2026 both William Blair and Raymond James maintained Outperform on Compass Therapeutics, Inc. (CMPX), marking a steady endorsement after the company’s Q4 results. The CMPX analyst rating appears unchanged by either firm, with Raymond James specifically citing the recent quarterly report. Investors should note small intraday declines of -1.34% and -1.52% reported alongside the reiterations and a market cap of $764,723,245